Astex Pharmaceuticals, a Cambridge, England, UK-based pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system (CNS), has become a strategic investor in The Dementia Discovery Fund.
Managed by venture capital firm SV Life Sciences, DDF is a (more than) $100M venture fund set up to promote innovation in dementia research and to support the next generation of drug discovery approaches for neurodegenerative disease.
A member of the Otsuka Group, based in Japan, Astex joined the DDF investor group which includes the UK Government’s Department of Health (DoH) and Alzheimer’s Research UK alongside major pharmaceutical companies including Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda. The company will participate in the Scientific Advisory Board of the DDF, which includes representatives from the other DDF strategic investors as well as academics, to share expertise, expand its collaborative networks and advise the investment team.
The DDF’s priorities are to explore and develop novel hypotheses in neurodegenerative diseases which could lead to new disease modifying treatments for dementia.